The estimated Net Worth of Atul Pande is at least $3.36 Milion dollars as of 1 December 2023. Atul Pande owns over 12,350 units of Immunovant Inc stock worth over $2,415,740 and over the last 9 years he sold IMVT stock worth over $490,666. In addition, he makes $454,232 as Independent Director at Immunovant Inc.
Sign up
Atul Pande IMVT stock SEC Form 4 insiders trading
Atul has made over 26 trades of the Immunovant Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 12,350 units of IMVT stock worth $490,666 on 1 December 2023.
The largest trade he's ever made was buying 15,000 units of Immunovant Inc stock on 30 September 2022 worth over $84,000. On average, Atul trades about 2,803 units every 35 days since 2016. As of 1 December 2023 he still owns at least 83,158 units of Immunovant Inc stock.
You can see the complete history of Atul Pande stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Atul Pande biography
Dr. Atul Pande M.D. serves as Independent Director of the Company. Since the closing of the Business Combination in December 2019, Dr. Pande has served as a member of Immunovant’s board of directors. Dr. Pande has extensive experience in treatment development across multiple disease areas. He is currently an independent board member of Axovant Gene Therapies, Karuna Therapeutics, Autifony Therapeutics, and Perception Neurosciences. He previously served as the Chief Medical Officer of PureTech Health, Chief Medical Officer of Tal Medical, and medical advisor to PureTech Health. Since April 2014, he has also served as President of Verity BioConsulting, a drug development consulting firm that provides services to clients in the biopharmaceutical business. From 2007 to April 2014, Dr. Pande was Senior Vice President and Senior Advisor, Pharmaceutical R&D at GlaxoSmithKline. He has also held senior roles at Pfizer R&D, Parke-Davis/Warner-Lambert and Lilly Research Laboratories. He has been on the Scientific Advisory Boards of Cennerv Pharma and Centrexion Corporation. Our board of directors believes that Dr. Pande’s medical background and his significant knowledge of the biopharmaceutical industry qualifies him to serve as a member of our board of directors.
What is the salary of Atul Pande?
As the Independent Director of Immunovant Inc, the total compensation of Atul Pande at Immunovant Inc is $454,232. There are 7 executives at Immunovant Inc getting paid more, with Peter Salzmann having the highest compensation of $8,806,830.
How old is Atul Pande?
Atul Pande is 65, he's been the Independent Director of Immunovant Inc since 2019. There are no older and 15 younger executives at Immunovant Inc.
What's Atul Pande's mailing address?
Atul's mailing address filed with the SEC is 320 W 37TH STREET, 6TH FLOOR, , NEW YORK, NY, 10018.
Insiders trading at Immunovant Inc
Over the last 5 years, insiders at Immunovant Inc have traded over $21,959,710 worth of Immunovant Inc stock and bought 3,433,213 units worth $88,718,319 . The most active insiders traders include Sciences Ltd. Roivant, Peter Salzmann a Julia G. Butchko. On average, Immunovant Inc executives and independent directors trade stock every 14 days with the average trade being worth of $1,150,148. The most recent stock trade was executed by Mark S. Levine on 21 August 2024, trading 3,295 units of IMVT stock currently worth $104,979.
What does Immunovant Inc do?
immunovant, inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. it develops imvt-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in phase iia clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of phase ii clinical trials for the treatment of warm autoimmune hemolytic anemia. the company is headquartered in new york, new york. immunovant, inc. is a subsidiary of roivant sciences ltd.
What does Immunovant Inc's logo look like?
Complete history of Atul Pande stock trades at Karuna Therapeutics Inc, Immunovant Inc a Axovant Gene Therapies
Immunovant Inc executives and stock owners
Immunovant Inc executives and other stock owners filed with the SEC include:
-
Peter Salzmann,
Chief Executive Officer, Director -
Pamela Connealy,
Chief Financial Officer -
Dr. Peter Salzmann M.B.A., M.D.,
CEO & Director -
Frank Torti,
Chairman of the Board -
Dr. Julia G. Butchko Ph.D.,
Chief Devel. & Technology Officer -
Andrew Fromkin,
Independent Director -
Douglas Hughes,
Independent Director -
Atul Pande,
Independent Director -
Dr. Frank M. Torti M.B.A., M.D., MBA,
Exec. Chairperson of the Board -
George Migausky,
Independent Director -
Eric Venker,
Director -
W. Bradford Middlekauff,
General Counsel -
Michael Elliott,
Chief Scientific Officer -
Julia Butchko,
Chief Development and Technology Officer -
Dr. William L. Macias M.D., Ph.D.,
Chief Medical Officer -
Lauren Schrier M.B.A.,
VP of Marketing -
Mark S. Levine,
Chief Legal Officer & Corp. Sec. -
Tom Dorney M.B.A., M.S.,
Director of Investor Relations & Strategy -
Eva Renee Barnett M.B.A.,
Chief Financial Officer -
Sciences Holdings, Llc Health,
10% owner -
Robert K Zeldin,
Chief Medical Officer -
Myrtle S Potter,
Director -
Jay S Stout,
Chief Technology Officer -
Rita Jain,
Chief Medical Officer -
William L. Macias,
Chief Medical Officer -
Eva Renee Barnett,
Chief Financial Officer -
Mark S. Levine,
Chief Legal Officer -
Sciences Ltd. Roivant,
-
Michael Geffner,
Chief Medical Officer